Oferta Tecnológica

Use of a compound in the prevention, improvement, treatment of mental disorders and behavior related to alcohol

  • Terapia

Alcohol is a psychoactive substance with properties that cause dependence, its consumption is widespread in society from an early age. The destructive consumption of alcohol increases the likelihood of suffering from noncommunicable and infectious diseases in addition to the social effects of excessive and prolonged consumption, which is associated with a large number of mental, physical and organic disorders.

It is of great importance to investigate new pharmacological treatments that contribute to modulate the consumption of alcohol, to prevent and / or treat the psychophysiological effects and the behavior of this drug. At present there are different specific treatments in the market; however, none of them are completely satisfactory, confering contraindications and side effects.

Lysophosphatidic acid (LPA) is a biologically active endogenous lysophospholipid present in multiple biological fluids such as plasma or blood. The LPA-mediated signaling system has been implicated in a large number of pathologies (fibrosis, cancer, sclerosis, inflammation, cardiovascular diseases) for which LPA receptor antagonist drugs are presented as a promising therapy.

This research group carried out a preclinical study, administering in vivo an antagonist of LPA receptor intraperitoneally in a systemic way, twenty minutes before ingesting alcohol.
The result was: a decrease in motivation to alcohol consumption, in the hypnotic – sedative effect, in cognitive deterioration and abstinence symptoms, all without producing aversion. In addition, normal state is recovered in less time and the drug does not affect individual’s health in relation to weight, food consumption, motivation by natural reinforcers or behavior.

 

You can also visit:

https://www.ibima.eu/grupo_investigacion/neuropsicofarmacologia/


Ventajas


  • This drug may have applications both in people diagnosed with substance dependence disorders and those who are not diagnosed as such.

  • The treatment is useful to reduce the desire to consume alcohol, also to prevent other effects of this drug, without resulting aversive.

  • Demonstrated high rate of efficacy.

  • Prevents or treats psychophysiological symptoms produced by alcohol intoxication and abstinence, also the cognitive and emotional deterioration induced by alcohol.

  • The repeated administration of this drug does not affect negatively the well-being of the individual, reducing the side effects and obtaining various beneficial effects on other related pathologies.

Palabras Clave


Clasificación

  • Substance abuse

Inventores de IBIMA


Contacto

Isabel Guerrero

Unidad de Innovación IBIMA
+34 951 440 260 ext.: 205 +34 671 534 901 Corp.: 63 49 01 isabel.guerrero@ibima.eu

María Mengual

Unidad de Innovación IBIMA
+34 951 440 260 ext.: 205 +34 689 008 050 maria.mengual@ibima.eu

Subscribe

Suscríbete a nuestro Newsletter y recibe en tu correo todas las últimas novedades del Instituto.
Consulta el histórico de Newsletter:

Calle Doctor Miguel Díaz Recio , 28 Málaga 29010

(+34) 951 440 260
Fax: (+34) 951 440 263